四天内，全球制药巨头完成三笔大额交易，总额超过180亿美元1。这一密集的资本运作背后，折射出跨国药企面对市场竞争的新策略——通过外部创新采购来强化产品管线。
诺华与中国本土生物技术公司艾博生物达成RNA疗法授权协议，艾博获得5.75亿美元首付款及最高72亿美元的里程碑付款1。同时，赛诺菲与美国生物制药企业再生元扩大抗体领域合作，再生元获得10亿美元预付款和最高70亿美元的里程碑付款1。此外，诺和诺德从恒瑞医药获得一款口服减重降糖药的全球独家权，首付款为3亿美元，潜在总金额最高可达26亿美元1。
这些交易在9月29日至10月2日期间陆续宣布1。其中，艾博生物成立于2019年，总部位于苏州1，此次与诺华的合作凸显了国内创新企业在全球医药市场中的地位提升。
Within four days, three major pharmaceutical transactions totaling more than $180 billion reshaped the industry's competitive landscape.1 The deals underscore a strategic shift among global drugmakers toward acquiring external innovation to maintain market position.
Novartis and Abogen Biotherapeutics reached an RNA therapy licensing agreement, with Abogen receiving an upfront payment of $575 million and potential milestone payments of up to $7.2 billion.1 Separately, Sanofi expanded its antibody collaboration with Regeneron, which secured a prepayment of $1 billion with the potential to earn up to $7 billion in additional milestone payments.1 In a third transaction, Novo Nordisk acquired global exclusive rights to an oral weight-loss and blood-sugar-lowering drug from Hutchison China MediTech, with an initial payment of $300 million and a maximum total deal value of $2.6 billion.1 These three agreements occurred on October 2, October 1, and September 29, 2026, respectively.1
The rapid succession of deals reflects how multinational pharmaceutical corporations are increasingly turning to external partnerships and acquisitions to sustain their competitive advantages. Rather than relying solely on internal research pipelines, these transactions demonstrate a deliberate strategy of licensing promising therapeutic candidates from emerging biotech firms and specialized developers to strengthen product portfolios in high-priority therapeutic areas.
评论
还没有评论，欢迎留下第一条。